AEZS - Aeterna Zentaris and Consilient Health in European Licensing Agreement for commercialization of macimorelin

Aeterna Zentaris ([[AEZS]] -5.2%) through its subsidiary has entered into an exclusive licensing agreement with Consilient Health, Ltd., a privately owned pharmaceutical company, for the commercialization of macimorelin in Europe and the United Kingdom.Consilient will be responsible for obtaining pricing and reimbursement approval in the European economic area and the United Kingdom, and bearing the regulatory cost for the label extension.Consilient to bear the regulatory cost for the label extension for pediatric use pending successful outcome of the upcoming safety and efficacy study, AEZS-130-P02 evaluating macimorelin for the diagnosis of CGHD; Phase 3 Study P02 is expected to be initiated in Q1 of 2021.Aeterna and Consilient also entered into a separate commercial supply agreement under which Consilient will purchase macimorelin from Aeterna and Aeterna will be responsible for supply and product quality.Consilient Health to make an up-front payment of EUR1M;  and will also pay to Aeterna royalties on net sales of

For further details see:

Aeterna Zentaris and Consilient Health in European Licensing Agreement for commercialization of macimorelin